European Heart Journal

• 

  Publication Venue For

  • Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation..  41:4037-4046. 2020
  • Antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention: balance best with double antithrombotic therapy. 2020
  • Towards a better standard for defining high bleeding risk patients: can we now translate this into a better practice?.  41:3750-3752. 2020
  • Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS..  41:3533-3545. 2020
  • Intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial..  41:3451-3458. 2020
  • Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes..  41:3132-3140. 2020
  • Prevention of cardiovascular disease: time for a course correction..  41:3016-3017. 2020
  • Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis..  41:2248-2258. 2020
  • Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)..  41:2109-2117. 2020
  • Novel approaches to the management of chronic systolic heart failure: future directions and unanswered questions..  41:1764-1774. 2020
  • Call me maybe? The right time and place for BPAs in EHRs..  41:1097-1099. 2020
  • Development of an international standard set of outcome measures for patients with atrial fibrillation: a report of the International Consortium for Health Outcomes Measurement (ICHOM) atrial fibrillation working group..  41:1132-1140. 2020
  • Managing patients with ST-elevation myocardial infarction and multivessel disease: is the story complete? 2020
  • Antithrombotic therapy after acute coronary syndrome and/or percutaneous coronary intervention in atrial fibrillation: finding the sweet spot..  40:3768-3770. 2019
  • Incidence of heart failure after pacemaker implantation: a nationwide Danish Registry-based follow-up study..  40:3641-3648. 2019
  • Must I keep taking all these medicines? Optimizing diuretics in chronic heart failure..  40:3613-3615. 2019
  • Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial..  40:3345-3352. 2019
  • Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial..  40:2801-2809. 2019
  • Management of cardiogenic shock complicating myocardial infarction: an update 2019..  40:2671-2683. 2019
  • Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk..  40:2632-2653. 2019
  • The optimal antithrombotic regimen to prevent post-CABG adverse events: an ongoing controversy..  40:2441-2443. 2019
  • Application of net reclassification index to non-nested and point-based risk prediction models: a review..  40:1880-1887. 2019
  • Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials..  40:1492-1500. 2019
  • Atrial fibrillation ablation in practice: assessing CABANA generalizability..  40:1257-1264. 2019
  • Risk stratification for stroke in atrial fibrillation: a critique..  40:1294-1302. 2019
  • Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial..  40:743-751. 2019
  • Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies..  40:621-631. 2019
  • Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF..  39:4255-4256. 2018
  • Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials..  39:3810-3820. 2018
  • Real-world clinical utility and impact on clinical decision-making of coronary computed tomography angiography-derived fractional flow reserve: lessons from the ADVANCE Registry..  39:3701-3711. 2018
  • An update on the journey towards precision medicine in cardiology..  39:3627-3628. 2018
  • The association between blood pressure and long-term outcomes of patients with ischaemic cardiomyopathy with and without surgical revascularization: an analysis of the STICH trial..  39:3464-3471. 2018
  • Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation..  39:2942-2955. 2018
  • Stroke prevention in atrial fibrillation: re-defining 'real-world data' within the broader data universe..  39:2932-2941. 2018
  • Uninterrupted apixaban for atrial fibrillation ablation is a reasonable alternative, but what is the significance of silent cerebral infarctions?.  39:2956-2958. 2018
  • Japan-United States of America Harmonized Assessment by Randomized Multicentre Study of OrbusNEich's Combo StEnt (Japan-USA HARMONEE) study: primary results of the pivotal registration study of combined endothelial progenitor cell capture and drug-eluting stent in patients with ischaemic coronary disease and non-ST-elevation acute coronary syndrome..  39:2460-2468. 2018
  • Diabetes and long-term outcomes of ischaemic stroke: findings from Get With The Guidelines-Stroke..  39:2376-2386. 2018
  • Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document..  39:2192-2207. 2018
  • Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative..  39:1687-1697. 2018
  • Traumatic injury: another unjustified reason to stop oral anticoagulation for atrial fibrillation..  39:1706-1708. 2018
  • Improving outcomes after catheter ablation of atrial fibrillation: better patient selection, better procedure, or both?.  39:450-452. 2018
  • Oral anticoagulation: a step toward solving the puzzle of dementia related to atrial fibrillation?.  39:461-463. 2018
  • Clopidogrel reloading for patients with acute myocardial infarction already on clopidogrel therapy..  39:193-200. 2018
  • Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials..  38:3502-3510. 2017
  • Staging classification of aortic stenosis based on the extent of cardiac damage..  38:3351-3358. 2017
  • Blood pressure and in-hospital outcomes in patients presenting with ischaemic stroke..  38:2827-2835. 2017
  • Interruption of non-vitamin K antagonist anticoagulants in patients undergoing planned invasive procedures: how long is long enough?.  38:2440-2443. 2017
  • Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF)..  38:2364-2373. 2017
  • Moving beyond regression techniques in cardiovascular risk prediction: applying machine learning to address analytic challenges..  38:1805-1814. 2017
  • HIV infection, ACS, PCI and high platelet reactivity: ingredients for a perfect thrombotic storm..  38:1687-1689. 2017
  • Infarct size, left ventricular function, and prognosis in women compared to men after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: results from an individual patient-level pooled analysis of 10 randomized trials..  38:1656-1663. 2017
  • Left atrial appendage occlusion: rationale, evidence, devices, and patient selection..  38:869-876. 2017
  • Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial..  38:648-660. 2017
  • A review of sex-specific benefits and risks of antithrombotic therapy in acute coronary syndrome..  38:165-171. 2017
  • The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial..  37:3576-3584. 2016
  • A view from the side-line..  37:3488-3489. 2016
  • Anticoagulation in coronary intervention..  37:3376-3385. 2016
  • Genetic cardiovascular risk prediction: are we already there?.  37:3279-3281. 2016
  • Risk stratification in non-ST elevation acute coronary syndromes: searching for the right formula..  37:3111-3113. 2016
  • The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial..  37:2869-2878. 2016
  • Outcomes of transfemoral transcatheter aortic valve implantation at hospitals with and without on-site cardiac surgery department: insights from the prospective German aortic valve replacement quality assurance registry (AQUA) in 17 919 patients..  37:2240-2248. 2016
  • Finerenone in heart failure: walking a fine line..  37:2115-2117. 2016
  • Left atrial appendage to great cardiac vein fistula complicating watchman left atrial appendage closure..  37:1602. 2016
  • The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation..  37:1582-1590. 2016
  • Genetic variants and disease: correlate or cause?.  37:1476-1478. 2016
  • Assessing generalizability of trial results in general practice..  37:1154-1157. 2016
  • Deciding about prolonged ticagrelor therapy in coronary clot formers: an ongoing dilemma..  37:1143-1144. 2016
  • CardioPulse: Platelet inhibitors and their differences..  37:323-326. 2016
  • Lessons learned and a look to the future: the Chronic Ischemic Heart Disease (CICD) Pilot Registry..  37:161-163. 2016
  • Nox4 NADPH oxidase: emerging from the veil of darkness..  36:3457-3459. 2015
  • Clinical outcomes of fractional flow reserve by computed tomographic angiography-guided diagnostic strategies vs. usual care in patients with suspected coronary artery disease: the prospective longitudinal trial of FFR(CT): outcome and resource impacts study..  36:3359-3367. 2015
  • Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial..  36:3268-3275. 2015
  • Management and outcomes in patients with moderate or severe functional mitral regurgitation and severe left ventricular dysfunction..  36:2733-2741. 2015
  • Augmenting outcomes in patients with advanced heart failure..  36:2276-2278. 2015
  • Cardiovascular precision medicine: hope or hype?.  36:1842-1843. 2015
  • Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 1: clinical trial design principles: A consensus document from the mitral valve academic research consortium..  36:1851-1877. 2015
  • Effect of genetic variations on ticagrelor plasma levels and clinical outcomes..  36:1901-1912. 2015
  • Current worldwide nuclear cardiology practices and radiation exposure: results from the 65 country IAEA Nuclear Cardiology Protocols Cross-Sectional Study (INCAPS)..  36:1689-1696. 2015
  • The detection and treatment of subclinical atrial fibrillation: evaluating the IMPACT of a comprehensive strategy based on remote arrhythmia monitoring..  36:1640-1642. 2015
  • Should patients on vitamin K antagonists be treated differently?.  36:1431-1433. 2015
  • Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial..  36:1264-1272. 2015
  • The end of an electrocardiographic dogma: a prominent R wave in V1 is caused by a lateral not posterior myocardial infarction-new evidence based on contrast-enhanced cardiac magnetic resonance-electrocardiogram correlations..  36:959-964. 2015
  • Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program..  36:669-675. 2015
  • Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension..  36:566-575. 2015
  • LCZ696: too good to be true?.  36:410-412. 2015
  • The association between biventricular pacing and cardiac resynchronization therapy-defibrillator efficacy when compared with implantable cardioverter defibrillator on outcomes and reverse remodelling..  36:440-448. 2015
  • Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial..  36:385-92a. 2015
  • Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial..  36:288-296. 2015
  • Predictors of blood pressure response in the SYMPLICITY HTN-3 trial..  36:219-227. 2015
  • Chest pain in patients with heart failure: why history may matter..  35:3408-3409. 2014
  • Atrial fibrillation, valvular heart disease, and use of target-specific oral anticoagulants for stroke prevention..  35:3323-3325. 2014
  • Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial..  35:3377-3385. 2014
  • Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry..  35:2864-2872. 2014
  • Ameliorating reperfusion injury in STEMI: dead or alive?.  35:2504-2506. 2014
  • Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial..  35:2516-2523. 2014
  • Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial..  35:2524-2529. 2014
  • Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial..  35:1864-1872. 2014
  • Is there a period of liability with initiation of warfarin in patients with atrial fibrillation?.  35:1834-1835. 2014
  • Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial..  35:1873-1880. 2014
  • Diagnosis of pheochromocytoma on physical examination..  35:1705. 2014
  • Statistical considerations in economic evaluations: a guide for cardiologists..  35:1652-1656. 2014
  • Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis..  35:1559-1567. 2014
  • The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial..  35:1541-1550. 2014
  • The organization, function, and outcomes of ST-elevation myocardial infarction networks worldwide: current state, unmet needs and future directions..  35:1526-1532. 2014
  • Early management of atrial fibrillation to prevent cardiovascular complications..  35:1448-1456. 2014
  • Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial..  35:1041-1050. 2014
  • The enigmatic search for optimal DAPT duration..  35:951-954. 2014
  • Large simple trials: really, it can't be that simple!.  35:549-551. 2014
  • Large streamlined trials in cardiovascular disease..  35:544-548. 2014
  • The appropriate and justified use of medical radiation in cardiovascular imaging: a position document of the ESC Associations of Cardiovascular Imaging, Percutaneous Cardiovascular Interventions and Electrophysiology..  35:665-672. 2014
  • Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis..  35:455-469. 2014
  • Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial..  35:224-232. 2014
  • Association between myocardial substrate, implantable cardioverter defibrillator shocks and mortality in MADIT-CRT..  35:106-115. 2014
  • Clinical course of atrial fibrillation in older adults: the importance of cardiovascular events beyond stroke..  35:250-256. 2014
  • Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF..  35:242-249. 2014
  • Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial..  35:233-241. 2014
  • Natriuretic peptide-guided heart failure management..  35:16-24. 2014
  • Learning from regional heterogeneity in outcomes of patients with acute myocardial infarction..  34:3171-3172. 2013
  • Physical activity in patients with stable coronary heart disease: an international perspective..  34:3286-3293. 2013
  • Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial..  34:3117-3127. 2013
  • Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF..  34:3128-3136. 2013
  • A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial..  34:2481-2489. 2013
  • Association between resting heart rate, chronotropic index, and long-term outcomes in patients with heart failure receiving β-blocker therapy: data from the HF-ACTION trial..  34:2271-2280. 2013
  • Atrial fibrillation: a spectrum of risk with a uniform treatment effect of novel anticoagulants?.  34:2429-2431. 2013
  • Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial..  34:2464-2471. 2013
  • Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial..  34:1723-1731. 2013
  • New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis..  34:1670-1680. 2013
  • Biomarkers in atrial fibrillation: a clinical review..  34:1475-1480. 2013
  • Phosphate: a novel cardiovascular risk factor..  34:1099-1101. 2013
  • Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis..  34:1204-1214. 2013
  • Evaluation of early percutaneous coronary intervention vs. standard therapy after fibrinolysis for ST-segment elevation myocardial infarction: contribution of weighting the composite endpoint..  34:903-908. 2013
  • Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review..  34:894-902d. 2013
  • Spousal depression, anxiety, and suicide after myocardial infarction..  34:649-656. 2013
  • How country-specific should a country-specific cost-effectiveness analysis be?.  34:166-167. 2013
  • Influence of baseline left ventricular function on the clinical outcome of surgical ventricular reconstruction in patients with ischaemic cardiomyopathy..  34:39-47. 2013
  • Mechanical dyssynchrony evaluated by tissue Doppler cross-correlation analysis is associated with long-term survival in patients after cardiac resynchronization therapy..  34:48-56. 2013
  • Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial..  33:2821-2830. 2012
  • Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice..  33:2782-2795. 2012
  • Clinical update: Remaining challenges and opportunities for improvement in percutaneous transradial coronary procedures..  33:2521-2526. 2012
  • Road mapping ATLAS ACS 2: are we there yet?.  33:2510-2512. 2012
  • Third universal definition of myocardial infarction..  33:2551-2567. 2012
  • Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document..  33:2403-2418. 2012
  • Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study..  33:2151-2162. 2012
  • The association of in-hospital major bleeding with short-, intermediate-, and long-term mortality among older patients with non-ST-segment elevation myocardial infarction..  33:2044-2053. 2012
  • Discriminating clinical features of heart failure with preserved vs. reduced ejection fraction in the community..  33:1734-1741. 2012
  • Putting risk prediction in atrial fibrillation into perspective..  33:1431-1433. 2012
  • Adjustment of the GRACE score by growth differentiation factor 15 enables a more accurate appreciation of risk in non-ST-elevation acute coronary syndrome..  33:1095-1104. 2012
  • Toward a therapeutic window for antiplatelet therapy in the elderly..  33:1187-1189. 2012
  • Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial..  32:2933-2944. 2011
  • Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes..  32:2945-2953. 2011
  • Long-term prognosis associated with J-point elevation in a large middle-aged biracial cohort: the ARIC study..  32:3098-3106. 2011
  • Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial..  32:2781-2789. 2011
  • Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy..  32:2412-2419. 2011
  • Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment..  32:2387-2394. 2011
  • RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome..  32:2541-2554. 2011
  • Who should have a routine early invasive approach after fibrinolytic therapy?.  32:1961-1963. 2011
  • Clinical evaluation of cardiovascular devices: principles, problems, and proposals for European regulatory reform. Report of a policy conference of the European Society of Cardiology..  32:1673-1686. 2011
  • Response to preventive cardiac resynchronization therapy in patients with ischaemic and nonischaemic cardiomyopathy in MADIT-CRT..  32:1622-1630. 2011
  • The future of clinical trials in secondary prevention after acute coronary syndromes..  32:1583-1589. 2011
  • Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study..  32:1519-1534. 2011
  • Additional impact of morning haemostatic risk factors and morning blood pressure surge on stroke risk in older Japanese hypertensive patients..  32:574-580. 2011
  • Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium..  32:205-217. 2011
  • Non-culprit coronary artery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction: insights from the APEX-AMI trial..  31:1701-1707. 2010
  • Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial..  31:1708-1716. 2010
  • Delay to reperfusion in patients with acute myocardial infarction presenting to acute care hospitals: an international perspective..  31:1328-1336. 2010
  • Factors related to heart rupture in acute coronary syndromes in the Global Registry of Acute Coronary Events..  31:1449-1456. 2010
  • Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis..  31:1257-1265. 2010
  • Towards a new order in cardiovascular medicine: re-engineering through global collaboration..  31:911-917. 2010
  • Clinical trials and registries in cardiovascular disease: competitive or complementary?.  31:520-521. 2010
  • Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The global registry of acute coronary events..  31:667-675. 2010
  • Resolution of ST-segment depression: A new prognostic marker in ST-segment elevation myocardial infarction..  31:573-581. 2010
  • The association of admission heart rate and in-hospital cardiovascular events in patients with non-ST-segment elevation acute coronary syndromes: results from 135 164 patients in the CRUSADE quality improvement initiative..  31:552-560. 2010
  • Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications..  31:227-235. 2010
  • Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial..  31:211-221. 2010
  • Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes..  31:50-58. 2010
  • Transfusion and mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention..  30:2575-2583. 2009
  • Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry..  30:2318-2326. 2009
  • Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial..  30:2226-2232. 2009
  • Reperfusion before percutaneous coronary intervention in ST-elevation myocardial infarction patients is associated with lower N-terminal pro-brain natriuretic peptide levels during follow-up, irrespective of pre-treatment with full-dose fibrinolysis..  30:2213-2219. 2009
  • Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial..  30:2019-2028. 2009
  • Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial..  30:1457-1466. 2009
  • Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT)..  30:1450-1456. 2009
  • Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials..  30:1245-1253. 2009
  • Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes..  30:1195-1202. 2009
  • Pre-operative homocysteine levels and morbidity and mortality following cardiac surgery..  30:995-1004. 2009
  • Reperfusion ventricular arrhythmia 'bursts' predict larger infarct size despite TIMI 3 flow restoration with primary angioplasty for anterior ST-elevation myocardial infarction..  30:757-764. 2009
  • Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes..  30:655-661. 2009
  • Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure..  30:338-345. 2009
  • ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007..  30:152-161. 2009
  • Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme..  29:3022-3028. 2008
  • Is thrombogenesis related to residual platelet function in ischaemic heart disease?.  29:3065. 2008
  • Modifiable risk factors control and its relationship with 1 year outcomes after coronary artery bypass surgery: insights from the REACH registry..  29:3052-3060. 2008
  • Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme..  29:2641-2650. 2008
  • Patterns and prognostic implications of low high-density lipoprotein levels in patients with non-ST-segment elevation acute coronary syndromes..  29:2480-2488. 2008
  • A smoker's paradox in patients hospitalized for heart failure: findings from OPTIMIZE-HF..  29:1983-1991. 2008
  • Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial..  29:1827-1833. 2008
  • Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in patients on dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad..  29:1729-1738. 2008
  • Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme..  29:1377-1385. 2008
  • Is female gender an independent risk factor for early mortality in coronary artery bypass surgery? (Abstract).  19 (Suppl):413-413. 1998
  • Risk stratification in coronary surgery.  19 (Suppl):413-413. 1998
  • The association between vegetation size and surgical treatment on 6-month mortality in left-sided infective endocarditis. 2019
  • Diuretic response in acute heart failure: clinical characteristics and prognostic significance. 2014